Author Affiliations: Division of Surgical Oncology, Department of Surgery, East Carolina University, Brody School of Medicine, Greenville, North Carolina.
An area of continuing controversy with regard to melanoma is the therapeutic value of a sentinel lymph node biopsy (SLNB). An interim analysis1 of the Multicenter Selective Lymphadenectomy Trial I failed to demonstrate an improvement in melanoma-specific survival for patients undergoing an SLNB compared with patients who were only observed. For this reason, some have questioned the role of an SLNB in an era when adjuvant therapy remains controversial.2- 4
Wong JH. Early Diagnosis of Metastatic Disease in Melanoma: Does It Make a Difference?Comment on “Long-term Follow-up and Survival of Patients Following a Recurrence of Melanoma After a Negative Sentinel Lymph Node Biopsy Result”. JAMA Surg. 2013;148(5):462. doi:10.1001/jamasurg.2013.1345